Publication at First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové |
2011
Abstract
Transtuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). This receptor is overexpressed in approximately 20% of gastric adenocarcinomas.